CAR T-cell Therapy
Chronic Lymphocytic Leukemia
Head & Neck Cancers
Immunotherapy in GU Cancers
Immunotherapy in Lung Cancer
Immunotherapy in Melanoma
Mantle Cell Lymphoma
Melanoma & Skin Cancer
Oncology Nursing News
Precision Medicine in Oncology
Special Reports in Personalized Cancer Care
SELECT A TOPIC
Attend An Event
State of the Science Summit
Regional Seminar Series
OS by PS in Metastatic Pancreatic Cancer Treatment- Data From an Exploratory Subgroup Analysis
<< View More Conferences
2017 European Hematology Association Congress
Oncology Conference Multimedia
View more videos >>
Dr. Hamlin on Results of Cerdulatinib in CLL, Follicular Lymphoma and T-Cell Lymphoma
Dr. Eskelund Discusses TP53 Mutated Mantle Cell Lymphoma
Dr. Ravandi on Vadastuximab Talirine Plus Hypomethylating Agents in AML
Oncology Conference Articles
Chemotherapy-Free Triplet Achieves 100% Response Rates in 3 Lymphoma Subtypes
The first known trial of combined ublituximab (TG-1101), ibrutinib (Imbruvica), and umbralisib (TGR-1202) showed that the combination was well tolerated and had activity across heavily pretreated patients with high-risk B-cell malignancies.
Ibrutinib/Venetoclax Yields Dramatic Blood Response in Patients With Relapsed/Refractory CLL
Combination ibrutinib (Imbruvica) and venetoclax (Venclexta) set the bar high and aims to achieve eradication of minimal residual disease within a year of treatment in patients with relapsed or refractory chronic lymphocytic leukemia.
Combination of Obinutuzumab and CC-122 Demonstrates Response in R/R Non-Hodgkin Lymphoma
The combination of obinutuzumab and CC-122 was well tolerated and demonstrated promising response rates and durable remissions in patients with relapsed or refractory diffuse large B-cell lymphoma, follicular lymphoma, and marginal zone lymphoma.
Polatuzumab Vedotin Demonstrates Durable Reponses in Follicular Lymphoma, DLBCL
Matthew J. Matasar, MD, discusses the potential of polatuzumab vedotin in patients with relapsed/refractory follicular lymphoma or diffuse large B-cell lymphoma.
CTL019 CAR T-Cell Therapy Strides Towards Approval in Pediatric and Young Adult Patients With ALL
CTL019, an investigational chimeric antigen receptor T-cell therapy, demonstrated high response rates and a manageable safety profile in pediatric and young adult patients with relapsed and/or refractory acute lymphoblastic leukemia.
Cerdulatinib Shows Promise in Relapsed/Refractory NHL
Paul A. Hamlin, MD, discusses his research with cerdulatinib in patients with certain types of non-Hodgkin lymphoma.
Comparison of Induction Therapies Prior to ASCT Favors Novel Quadruple Over Triplet Regimens
Results from the phase III Myeloma XI study showed that patients with myeloma had deeper responses after induction and after allo-stem cell transplantation with outpatient-delivered quadruplet therapy than with sequential immunomodulatory triplet combinations.
Ixazomib Maintenance Shows Robust Activity in Multiple Myeloma
Patients with newly-diagnosed multiple myeloma who did not elect to undergo stem cell transplant but remained on single agent ixazomib maintenance fared as well as those who received SCT.
Response Rate Hits 100% for bb2121 in Multiple Myeloma
All patients with multiple myeloma in a phase I study showed a response following treatment with an active dose of bb2121, an investigational anti–BCMA CAR T-cell construct.
Biomarkers Emerge for Severe Neurotoxicity Risk After CAR T-Cell Therapy
Investigators reported the characterization of early clinical and serum biomarkers that may identify specific patients with ALL being treated with 19-28z chimeric antigen receptor T cells needing an early intervention to mitigate the development of severe neurotoxicity.
Beyond Midostaurin: Advances Continue With FLT3 Inhibitors in AML
Jorge E. Cortes, MD, discusses ongoing advances with FLT3 inhibitors in acute myeloid leukemia.
FDA Approval in HCC, Breakthrough Designation in MCL, and More
Dabrafenib/Trametinib Combo Induces High Responses in BRAF V600E-Mutant Biliary Tract Cancer
Treatment Goals in Refractory mCRC
FDA Approves Third Trastuzumab Biosimilar
Olaratumab Falls Short in Phase III Soft Tissue Sarcoma Trial
Covering Every Angle of Oncology Practice. Click a cover below, to view more.
American Journal of Managed Care
Oncology Nursing News
Physicians' Education Resource
Physician's Money Digest
Specialty Pharmacy Times
Terms & Conditions
2 Clarke Drive
Cranbury, NJ 08512
Copyright OncLive 2006-2018
Intellisphere, LLC. All Rights Reserved.